Fisher & Paykel Healthcare announced results for the first half of the 2024 financial year, reporting a 26% increase over the prior comparable period in its homecare product group, which includes products used in the treatment of obstructive sleep apnea (OSA) and respiratory support in the home.    

In the homecare product group, OSA masks and accessories revenue increased 28% in constant currency. 

“Our first half result indicates a continuation of stable ordering patterns in our hospital business and a robust performance for homecare,” says Fisher & Paykel managing director and CEO Lewis Gradon in a release. 

Total revenue for the homecare product group was $314.4 million.

Evora Full has been available in the United States for more than a year, and it continues to see impressive demand and positive customer feedback,” says Gradon in the release. “We are set to build on this momentum next year as our revolutionary new F&P Solo mask is rolled out beyond New Zealand and Australia.” 

Additional key results for the first half of the 2024 financial year included:

  • 12% increase in net profit after tax to $107.3 million, 22% increase in constant currency
  • 16% increase in operating revenue to $803.7 million, 16% increase in constant currency
  • 11% increase in hospital operating revenue to $487.5 million, 11% increase in constant currency
  • 19% increase in constant currency for new applications consumables (products used in noninvasive ventilation, Optiflow nasal high flow, and surgical applications) accounting for 70% of hospital consumables revenue
  • 26% increase in homecare operating revenue to $314.4 million, 25% increase in constant currency
  • 28% increase in constant currency for OSA masks and accessories revenue
  • Investment in research and development was 12% of revenue, or $96.9 million

Photo caption: Evora Full

Photo credit: Fisher & Paykel Healthcare